Study drug for HER2-negative, advanced breast cancer after prior treatment
Part of Cancer, Skin clinical trials.
This Phase 2 trial tests patritumab deruxtecan (U3-1402) in people with HER2-negative, hormone-receptor positive (HR+) breast cancer that cannot be removed by surgery or has spread. It’s for cancers that have progressed despite endocrine therapy plus a CDK4/6 inhibitor, aiming to shrink tumors and control the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are an adult with HR+ and HER2-negative breast cancer that has spread or cannot be removed surgically
- Your cancer has shown progress on scans after treatment with a CDK4/6 medicine plus hormone (endocrine) therapy
- You have had standard chemotherapy for advanced breast cancer, but no more than one prior line in that advanced setting
- There is a spot that doctors can safely biopsy (except bone-only metastases), and you have at least one measurable tumor spot on imaging
- You can do the study visits (ECOG performance status 0–1) and are expected to live at least 12 weeks
- Your organ tests and blood counts are adequate, and if you can become pregnant (or can cause pregnancy), you agree to strict birth control rules
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new drug called HER3-DXd (alone or combined with other medicines) for people with advanced breast cancer that has already been treated with T-DXd (Enhertu) and then got worse. The goal is to see if the new drug can shrink tumors safely.
This trial tests two antibody-drug conjugates (Enhertu and Datroway) for breast cancer that is HER2-low or HER2-0. It aims to find the best treatment sequence for people whose cancer has stopped responding to prior therapy.
This Phase 1 trial tests a combination of immune-targeting drugs (a CD40 medicine and a substance that helps immune cells act) plus chemotherapy in people with HER2-negative advanced breast cancer that has progressed. It aims to find a safer dose and see whether the treatment can shrink tumors or slow the cancer.
This trial tests a new drug called patritumab deruxtecan (a targeted therapy) for people with a common type of advanced breast cancer (HR+/HER2-). It's for those whose cancer has grown despite treatment with a CDK4/6 inhibitor plus hormone therapy.
This trial tests a new drug, patritumab deruxtecan, combined with other cancer treatments for people with advanced HER2+ breast cancer that cannot be removed by surgery. It may be an option if you have already tried other HER2-targeted therapies.
This trial tests a new combination of two targeted drugs (patritumab deruxtecan and trastuzumab deruxtecan) for people with hormone receptor-positive breast cancer that has low or ultralow levels of HER2 and has spread or cannot be removed by surgery. The goal is to see if the combination works better than current treatments.
Hear when a new Metastatic Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.